|
|
|
715
|
A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) Versus HLA-Haploidentical Related Bone Marrow (Haplo-BM) for Patients With Hematologic Malignancies (BMT CTN #1101) |
III |
Immunotherapy |
Not Applicable |
|
UPCC 11411
|
Maintenance Lenalidomide in Lymphoma |
I / II |
Immunotherapy |
lenalidomide |
|
UPCC 24412
|
A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS-936558) in Subjects With Relapsed or Refractory Hematologic Malignancy |
I |
Immunotherapy |
BMS-936558 |